March 31, 2023
March 31, 2023 – Camber Pharmaceuticals, Inc. is voluntarily recalling lot # E220182 of Atovaquone Oral
Suspension, USP 750mg/5mL to the Consumer/User level
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
News
March 29, 2023
March 29, 2023, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone
hydrochloride nasal spray for over-the-counter (OTC), nonprescription use – the first naloxone product
approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of
opioid overdose and is the standard treatment for opioid overdose.
March 29, 2023
March 29, 2023 - The FDA approved Emergent BioSolutions’ Narcan (naloxone hydrochloride) 4 mg
nasal spray as an over-the-counter (OTC) emergency treatment for opioid overdose
March 27, 2023
FDA is notifying pharmacists that the recommendation in the Buprenorphine-containing Transmucosal
products for Opioid Dependence (BTOD) REMS program
March 27, 2023
On March 27, 2023 Novartis reported topline results from the NATALEE trial, stating that Kisqali
(ribociclib) plus endocrine therapy significantly reduced the risk of disease
March 24, 2023
March 24, 2023 - Pharming Group N.V. has announced that the US Food and Drug Administration (FDA)
has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide
March 22, 2023
March 22, 2023 - Ascend Laboratories LLC. is voluntarily recalling Dabigatran Etexilate Capsules. USP 75
mg and 150 mg to the consumer/user level due to the presence
March 22, 2023
March 22, 2023 - Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC today announced that the U.S.
Food and Drug Administration